The renal cell carcinoma market is witnessing a substantial change, largely fueled by label expansions of immune checkpoint inhibitor therapies. Combination regimens, including Opdivo plus Yervoy (Bristol Myers Squibb / Ono Pharmaceutical) and Keytruda (Merck & Co.) plus Inlyta (Pfizer), are revolutionizing the treatment of advanced disease. The approval and uptake of Opdivo plus Cabometyx (Exelixis / Ipsen) and Keytruda plus Lenvima / Kisplyx (Eisai) will also drive fierce competition in this setting. Treatment choices for early-stage disease are also increasing with Keytruda’s label expansion as an adjuvant therapy. Moreover, the FDA’s approval of Welireg (Merck & Co.) will reshape the treatment of VHL-associated tumors. The anticipated entry of other agents such as savolitinib (AstraZeneca) will further diversify treatment options during the forecast period and create a highly competitive and dynamic market.
Questions answered
What is the size of the early-stage and advanced / metastatic drug-treatable renal cell carcinoma population, and how will drug-treatment rates change over time?
What is the expected market impact of recent drug approvals and label expansions of novel combinations incorporating Opdivo, Cabometyx, Welireg, Lenvima / Kisplyx, and Keytruda for renal cell carcinoma?
Which are the most promising emerging therapies in the late-phase pipeline, and how will they shape the future of the renal cell carcinoma market?
What are the drivers and constraints in renal cell carcinoma, and how will the market evolve over the forecast period?
Product Description
Disease Landscape & Forecast provides comprehensive market intelligence with world-class epidemiology, keen insight into current treatment paradigms, in-depth pipeline assessments, and drug forecasts supported by detailed primary and secondary research.
Solution Enhancement
Disease Landscape & Forecast will feature continual updates in 2022 to provide timely insights and analyses as meaningful indication-specific news and events unfold.
Market share of drug classes for renal cell carcinoma: 2021
Market share of drug classes for renal cell carcinoma: 2031
Drug-treatable population share and major-market sales share in renal cell carcinoma: 2021
Drug-treatable population share and major-market sales share in renal cell carcinoma: 2031
Population positioning of current therapies in renal cell carcinoma
Population positioning of emerging therapies in renal cell carcinoma
Renal cell carcinoma SWOT analysis
Market drivers and constraints
What factors are driving the market for renal cell carcinoma?
What factors are constraining the market for renal cell carcinoma?
Major-market sales for renal cell carcinoma by drug-treatable population: 2021-2031
Major-market sales of immune oncology therapies for renal cell carcinoma: 2021-2031
Major-market sales of angiogenesis inhibitors for renal cell carcinoma: 2021-2031
Segment-specific trends
Patient-share dynamics of therapies for early-stage (stage I-III) renal cell carcinoma, United States: 2021-2031
Patient-share dynamics of key therapies in first-line advanced or metastatic renal cell carcinoma, United States: 2021-2031
Patient-share dynamics of key therapies in first-line advanced or metastatic renal cell carcinoma, Japan: 2021-2031
Patient-share dynamics of key therapies in second-line advanced or metastatic renal cell carcinoma, United States: 2021-2031
Patient-share dynamics of key therapies in second-line advanced or metastatic renal cell carcinoma, Japan: 2021-2031
Patient-share dynamics of key therapies in third-line advanced or metastatic renal cell carcinoma, United States: 2021-2031
Patient-share dynamics of key therapies in third-line advanced or metastatic renal cell carcinoma, Japan: 2021-2031
Patient-share dynamics of key therapies in fourth-line advanced or metastatic renal cell carcinoma, United States, 2021-2031
Patient-share dynamics of key therapies in fourth-line advanced or metastatic renal cell carcinoma, Japan: 2021-2031
Forecast
Market forecast assumptions
Market forecast dashboard
Etiology and pathophysiology
Disease overview
Progression of renal cell carcinoma
Anatomy and histology of renal cell carcinoma
Prognostic models for renal cell carcinoma
International Metastatic RCC Database Consortium risk assessment system for stage IV renal cell carcinoma
UCLA Integrated Staging System for renal cell carcinoma
Classification of renal cell carcinoma
Staging of renal cell carcinoma
TNM staging system for renal cell carcinoma
Definitions of the TNM staging system for renal cell carcinoma
Key pathways and drug targets for renal cell carcinoma
Epidemiology
Key findings
Key updates
Epidemiology populations
Disease definition
Methods
Sources used for diagnosed incidence of renal cell carcinoma
Diagnosed incident cases of renal cell carcinoma: 2021-2031
Disease definition
Methods
Sources used for stage distribution of renal cell carcinoma
Diagnosed incident cases of renal cell carcinoma by stage distribution: 2021-2031
Disease definition
Methods
Sources used for recurrent incidence of renal cell carcinoma
Recurrent incident cases of renal cell carcinoma: 2021-2031
Renal cell carcinoma patient flow
Drug-Treatable Cases of Renal Cell Carcinoma: 2020-2030
Drug-treated cases of renal cell carcinoma: 2021-2031
Current treatment
Key findings
Treatment goals
Key endpoints used in clinical trials for renal cell carcinoma
Key current therapies
Overview
Mechanism of action of key current drug classes used for renal cell carcinoma
Current treatments used for renal cell carcinoma
Market events influencing the use of key current therapies in renal cell carcinoma
Key results from select clinical trials investigating Opdivo for the treatment of renal cell carcinoma
Ongoing clinical development of Opdivo
Key ongoing clinical trials of Opdivo in the treatment of renal cell carcinoma
Expert insight: Opdivo
Key results from select clinical trials investigating Opdivo and Yervoy combination therapy for the treatment of renal cell carcinoma
Ongoing clinical development of Opdivo and Yervoy combination therapy
Key ongoing clinical trials of Opdivo and Yervoy combination therapy in the treatment of renal cell carcinoma
Expert insight: Opdivo and Yervoy combination therapy
Key results from select clinical trials investigating Keytruda for the treatment of renal cell carcinoma
Ongoing clinical development of Keytruda
Key ongoing clinical trials of Keytruda in the treatment of renal cell carcinoma
Expert insight: Keytruda
Key results from select clinical trials investigating Bavencio for the treatment of renal cell carcinoma
Ongoing clinical development of Bavencio
Expert insight: Bavencio
Key results from select clinical trials investigating Sutent for the treatment of renal cell carcinoma
Expert insight: Sutent
Key results from select clinical trials investigating Votrient for the treatment of renal cell carcinoma
Expert insight: Votrient
Advantages and disadvantages of Nexavar
Expert insight: Nexavar
Key results from select clinical trials investigating Inlyta for the treatment of renal cell carcinoma
Expert insight: Inlyta
Expert insight: Avastin
Key results from select clinical trials investigating Cabometyx for the treatment of renal cell carcinoma
Ongoing clinical development of Cabometyx
Key ongoing clinical trials of Cabometyx in the treatment of renal cell carcinoma
Expert insight: Cabometyx
Key results from select clinical trials investigating Lenvima / Kisplyx for the treatment of renal cell carcinoma
Ongoing clinical development of Lenvima / Kisplyx
Expert insight: Lenvima / Kisplyx
Key results from select clinical trials investigating Fotivda for the treatment of renal cell carcinoma
Ongoing clinical development of Fotivda
Key ongoing clinical trials of Fotivda in the treatment of renal cell carcinoma
Expert insight: Fotivda
Advantages and disadvantages of Torisel
Expert insight: Torisel
Ongoing clinical development of Afinitor
Key ongoing clinical trials of Afinitor in the treatment of renal cell carcinoma
Expert insight: Afinitor
Key results from select clinical trials investigating Welireg for the treatment of renal cell carcinoma
Ongoing clinical development of Welireg
Key ongoing clinical trials of Welireg in the treatment of renal cell carcinoma
Expert insight: Welireg
Medical practice
Early-stage renal cell carcinoma: stages I-III
First-line advanced or metastatic renal cell carcinoma: stage IV
Second- and subsequent-line advanced or metastatic renal cell carcinoma
Patient characteristics influencing drug selection in renal cell carcinoma
Treatment decision tree for renal cell carcinoma: United States
Treatment decision tree for renal cell carcinoma: EU5
Treatment decision tree for renal cell carcinoma: Japan
Unmet need overview
Current and future attainment of unmet needs in renal cell carcinoma
Top unmet needs in renal cell carcinoma: current and future attainment
Expert insight: unmet need in renal cell carcinoma
Emerging therapies
Key findings
Key emerging therapies
Key therapies in development for renal cell carcinoma
Estimated market authorization dates of key emerging therapies for the treatment of renal cell carcinoma
Analysis of clinical development program for Tecentriq
Key ongoing clinical trials of Tecentriq in the treatment of renal cell carcinoma
Expert insight: Tecentriq
Key results from select clinical trials investigating tremelimumab and Imfinzi combination therapy for the treatment of renal cell carcinoma
Analysis of the clinical development program for Imfinzi
Key ongoing clinical trials of Imfinzi in the treatment of renal cell carcinoma
Expert insight: Imfinzi
Expectations for market authorization and sales opportunity of Imfinzi in renal cell carcinoma
Key results from select clinical trials investigating tremelimumab and Imfinzi combination therapy for the treatment of renal cell carcinoma
Analysis of clinical development program for tremelimumab and Imfinzi combination therapy
Key ongoing clinical trials of tremelimumab and Imfinzi combination therapy in the treatment of renal cell carcinoma
Expert insight: tremelimumab and Imfinzi combination therapy
Expectations for market authorization and sales opportunity of tremelimumab and Imfinzi combination therapy in renal cell carcinoma
Analysis of clinical development program for quavonlimab
Key ongoing clinical trials of quavonlimab in the treatment of renal cell carcinoma
Expert insight: quavonlimab
Expectations for market authorization and sales opportunity of quavonlimab in renal cell carcinoma
Key results from select clinical trials investigating Orpathys for the treatment of renal cell carcinoma
Analysis of clinical development program for Orpathys
Key ongoing clinical trials of Orpathys in the treatment of renal cell carcinoma
Expert insight: Orpathys
Expectations for market authorization and sales opportunity of Orpathys in renal cell carcinoma
Key results from select clinical trials investigating abexinostat for the treatment of renal cell carcinoma
Analysis of clinical development program for abexinostat
Key ongoing clinical trials of abexinostat in the treatment of renal cell carcinoma
Expert insight: abexinostat
Expectations for market authorization and sales opportunity of abexinostat in renal cell carcinoma
Early-phase pipeline analysis
Select compounds in early-phase development for renal cell carcinoma
Access and reimbursement overview
Region-specific reimbursement practices
Key market considerations in renal cell carcinoma: United States
General reimbursement environment: United States
Key market access considerations in renal cell carcinoma: EU5
General reimbursement environment: EU5
Key market access considerations in renal cell carcinoma: Japan
General reimbursement environment: Japan
Appendix
Abbreviations
Renal cell carcinoma bibliography
Kiran Bountra
Kiran Bountra, M.Res., Ph.D., Senior Healthcare Research & Data Analyst, Oncology. Dr. Bountra has a background in the biotechnology sector, specializing in target validation and small-molecule drug discovery. Before joining Clarivate, he worked as a senior scientist at OMass Therapeutics, with a focus on basal cell carcinoma and epilepsy programs. Previously, he trained as a structural biologist, researching the mechanisms of transport proteins involved in drug resistance. He holds a Ph.D. in biochemistry from Imperial College London.
Mudasir Khan, M.P.H.
Mudasir Khan, M.P.H., is a senior epidemiologist at Clarivate. His areas of expertise are oncology and psychiatry. He holds a master’s degree in public health from the Tata Institute of Social Sciences in Mumbai.
Sorcha Cassidy, M.Res., Ph.D.
Sorcha Cassidy, M.Res., Ph.D., is an associate director on the Oncology team at Clarivate. She manages a team of analysts who produce syndicated primary and secondary market research reports and custom analysis on a wide range of oncology indications. Dr. Cassidy also provides client support for all oncology products and has expertise in hematologic malignancies and CAR T-cell therapies. She has published oncology market assessment articles in Nature Reviews Drug Discovery. Previously, Dr. Cassidy was a market research manager at Janssen UK. She obtained her M.Res. and Ph.D. in immunology from Imperial College London, where she investigated the role of innate immune modulators (killer immunoglobulin-like receptors [KIRs]) on natural killer cells in various diseases.